EP Lab Digest - December 2007 - (Page 33)

DECEMBER 2007 NEWS 33 Boston Scientific and GE Healthcare Announce their First Patient Data Link to Electronic “T Medical Record Continued from page 1 he integration uses Boston Scientific’s LATITUDE ® Patient Management system to allow clinicians to access information from a patient’s implanted cardiac device and store within the GE Centricity® Electronic Medical Record (EMR) system in the form of lab results. “Having electronic access to a more comprehensive medical record enables me to provide even better care for my device patients,” said R. Jeffrey Westcott, MD, Director, Cardiac Catheterization Laboratory, Swedish Heart and Vascular Institute, Seattle, Washington. “The additional upside is less paperwork and the ability to easily collaborate with other physicians who are managing other aspects of the patient’s care.” “The collaboration between GE Healthcare and Boston Scientific provides a more comprehensive patient record and enables physicians to make more accurate decisions regarding their patients,” said Dr. Scott Hessen, Chief, Clinical Cardiac Electrophysiology, Cardiology Consultants of Philadelphia, Pennsylvania. GE’s Centricity EMR is an electronic medical record system that enables ambulatory care physicians and clinical staff to document patient encounters, streamline clinical workflow, and securely exchange clinical data with other providers, patients, and information systems. Among the most widely used ambulatory care electronic medical records, Centricity EMR empowers healthcare providers to deliver the highest quality of care at lower costs. Boston Scientific’s LATITUDE Patient Management system is designed to remotely monitor specific device and cardiac status information for physicians, which gives patients peace of mind knowing their device is being monitored on a scheduled basis. Since LATITUDE Patient Management was first introduced in 2005, more than 70,000 patients have been enrolled on the system at more than 1,700 clinics across the United States. The system is designed to promote compliance among patients while also enabling physicians to intervene earlier in a patient’s care with actionable data. Available as an optional component to the LATITUDE Patient Management system are a wireless weight scale and blood pressure cuff, which are aligned with the ACC/AHA physician society guidelines that recommend monitoring weight and blood pressure. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia Continued from page 1 receptor gene variants (beta-1 389 Arg/Arg and Gly carriers). In the adrenergic receptor genetic substudy, chronic administration of bucindolol resulted in a significant reduction in cardiovascular hospitalizations and mortality. Effects on both were strikingly beta-1 389 Arg/Gly specific, with the higher functioning, Arg/Arg version of the receptor associated with large treatment effects (compared to placebo, reduction in time to event CV hospitalizations by 34% [p = 0.003], CV hospitalizations/patient by 35% [p = 0.005], number of days CV hospitalized/patient by 36% [p = 0.005], and cardiovascular mortality by 46% [p = 0.015]). The presentation concluded that genetic targeting of the beta-1 AR 389 polymorphism may improve the clinical responses to bucindolol for CV mortality and morbidity. “Effect of b1 389 Arg/Gly a2c 322-325 Wt/Del Genotypes on Adjudicated Hospitalizations in the BEST Trial” (Presentation #2912) presented, in an oral presentation by Dr. Peter Carson of the Virginia Medical Center, data from a recent adjudication by the BEST ninemember endpoints committee (EPC), in which they reviewed all 5,086 hospitalizations from the study, recognized by the FDA as an important endpoint in evaluating heart failure drugs. The analysis revealed that the EPC method — due to its level of specificity — adjudicated fewer hospitalizations due to worsening heart failure as compared to the investigator/CRF method. In T he data presented provided us with more evidence supporting the potential of bucindolol as a targeted therapy for the treatment of heart failure,” said Michael R. Bristow, MD, PhD, chief science and medical officer of ARCA. “Importantly, we are encouraged by the data demonstrating bucindolol’s effect in preventing atrial fibrillation and life-threatening ventricular arrhythmias, showing the promise for bucindolol in additional indications. In addition, the BEST trial investigators were able to extend the observation of pharmacogenetic targeting of bucindolol to benefits on cardiovascular hospitalizations, which in effect gives the drug and targeting concept a broader application.” “Effects of Bucindolol on Cardiovascular Mortality and Morbidity Determined by the Beta1 389 Arg/Gly Receptor Polymorphism Data from a substudy analysis of the BEST cohort” (Presentation #901) presented by Michel White, MD from the Montreal Heart Institute, demonstrated that in the entire 2,708 patient cohort of BEST, chronic administration of bucindolol results in a significant reduction in cardiovascular hospitalizations, as well as in the previously reported heart failure hospitalizations and cardiovascular mortality. In addition, results were reported from the large (1,040 patient) DNA substudy of BEST, a hypothesis-driven, prospectivelydesigned study initiated during the trial that examined the effects of bucindolol in beta-1 adrenergic See NEWS page 40

Table of Contents Feed for the Digital Edition of EP Lab Digest - December 2007

EP Lab Digest - December 2007 Improved Anatomical Orientation During AF Catheter Ablation: Experience from Leipzig Heart Center One EP Lab’s Solution to the Administration of Deep Sedation Contents Letter from the Editor Spotlight Interview: Northeast Georgia Medical Center Emerging Technologies for the Electrophysiology Lab The Western Atrial Fibrillation Symposium About the PRECEDE-HF Trial: Interview with William T. Abraham, MD, FACP, FACC, FAHA Overview on Shire and the Discontinuation of Ethmozine®: After the Heart Rhythm Society Intervenes, the Company Changes its Decision Minimizing the Risk of Infection at Children’s Sibley Heart Center: Interview with Nicole Jarrell, RNC, MSN, and J. Renee Watson, RN, CIC Is There a Link Between Gasoline Vapors and Brugada Syndrome? Interview with Darko Kranjcec, MD and Hugues Abriel, MD, PhD New Feature! Pacemaker/ICD Puzzle Email Discussion Group Events Calendar Industry News and Products

EP Lab Digest - December 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.